Ghisallo Capital Management’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Ghisallo Capital Management’s Portfolio DMIIR Stock Details DMIIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.5K	Hold	750,000	–	–	﹤0.01%	336
2026 Q1	$60K	Hold	750,000	–	–	﹤0.01%	274
2025 Q4	$105K	Buy	+750,000	New	+$107K	﹤0.01%	205

Other funds holding DMIIR

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

Ghisallo Capital Management's DMIIR Position: Q2 2026 in Review

Ghisallo Capital Management held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q2 2026 at 750,000 shares worth $54.5K. The position accounts for ﹤0.01% of the portfolio, ranked #336.

Ghisallo Capital Management first reported a position in DMIIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $105K in Q4 2025. 61 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

Ghisallo Capital Management held 750,000 shares of Drugs Made In America Acquisition II Corp Right worth $54.5K as of Q2 2026.
Ghisallo Capital Management left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q2 2026.
Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Ghisallo Capital Management's portfolio in Q2 2026, its #336 holding.
Ghisallo Capital Management first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 3 quarters since.
Ghisallo Capital Management's Drugs Made In America Acquisition II Corp Right position peaked at $105K in Q4 2025.
61 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.